



Funded by the Horizon 2020
Framework Programme of the
European Union

Zika

Preparedness Latin American Network

16 June 2016

*Prof Annelies Wilder-Smith
Umeå Centre for Global Health Research
Epidemiology and Global Health*

Call for proposals
Feb. 2016

Deadline
April 2016

Review finalized
July 2016

Starting date
Oct. 2016

...




CO: Carlo Giaquinto,
University of Padua /
PENTA Foundation,
Italy



CO: Annelies
Wilder-Smith, Umea
University, Sweden



CO: Xavier de Lamballerie, Aix-Marseille University / INSERM, France



Harmonization of data and a roadmap towards data sharing

1. To **harmonize** the protocols and standardize the tools for data capture and data management

- 1.1. Harmonization of protocols
- 1.2. Standardization of data capture tools and data management

2. To set up joint **harmonized** platforms for clinical research

- 2.1. To set up a reciprocal clinical monitoring platform
- 2.2. To set up a joint laboratory diagnostics EQA platform
- 2.3. To set up a virtual joint biobanking platform
- 2.4. Establishing principles of governance for the joint virtual biobanking platform

3. To **share** data in real time in the collaborative environment of the three EC-funded consortia

- 3.3. Monitoring enrolment and accrual of patients across geography
- 3.4. Joint analysis plan



Comparison between 3 EU Zika consortia

ZIKAlliance

- **Asymptomatic PW cohorts:**
- **Children cohorts**
- **Natural history cohorts**
- **Seroprevalence studies**
- **Virology and Basic Science**
- **Modelling**
- **Entomology**
- **Preparedness network**

ZIKAction

- **Asymptomatic PW cohorts:**
- **Children cohorts**
- **Case-control studies**
- **Preparedness network**

ZIKAPlan


- **Symptomatic PW cohorts:**
- **Children cohorts**
- **Seroprevalence**
- **Modelling**
- **Birth defect surveillance**
- **Travellers cohorts**
- **Neuro-Zika**
- **Entomology**
- **Preparedness network**



What are the attack rates?

Pathogenesis

D



Asymptomatic to symptomatic ratio and its impact on CZS

Asymptomatic Prenatal Zika Virus Infection and Congenital Zika Syndrome

Enny S. Paixao,¹ Wei-Yee Leong,² Laura C. Rodrigues,^{1,a} and Annelies Wilder-Smith^{1,2,3,a}

Prospective studies (442-2596 pregnant women with lab confirmed ZIKV)

38-61% of pregnant women with lab confirmed Zika infection are symptomatic

5-6% of symptomatic infections result in CZS

5-7% of asymptomatic infections result in CZS

What are the implications?


All pregnant women need to be screened

High bar for vaccine development: sterilizing immunity needed?

Objectives, Study population and data collection

Sources: (1) infants who have been followed since the beginning of the epidemic; (2) case-control study

- 1. Born with microcephaly
- 2. Born to infected women



* After 24th month, the follow up will be annual: 36th and 48th month

Principal outcomes to be compared: **evolution of head circumference, clinical, dental and neurological disorders, neurodevelopment, epilepsy, ophtalmologic and audiologic impairment, death.**

Microcephaly ... And what else?

microcephaly



abortion

stillbirth

normal at birth

epilepsy

visual deficit

hearing loss

arthrogryposis

intracranial calcifications
without microcephaly

intrauterine growth restriction

mental retardation?

endocrine diseases?

psychiatric disorders?

learning difficulties?

normal at birth with
manifestations that
occur later in life


attention deficit disorder (ADD)

autism?

GBS during outbreak of Zika Infection in French Polynesia (2013-2014)

[Population census 2012: 268,270 inhabitants]
Lancet February 29, 2016

- Risk of GBS was **0.24 per 1000 Zika infections** (1 per 4000 infected patients)
- Mean Age **42 ys** (IQR 36-56)
- 31 Men (74%)
- History of viral illness in **88%**
- Median of **6 days** [IQR 4-10] before onset of GBS
- Median Progression of neuro symptoms to nadir was 4 days [IQR 4-9]
- Plateau phase 4 days [IQR 3-10]
- Clinical outcome 3 months after:
 - **24 (57%)** patients were able to walk without assistance



Clinical Features


- Generalized muscle weakness **74%**
- Inability to walk **44%**
- Facial palsy **64%**
- Admission to ICU **38%**
- Respiratory support **29%**
- Neurophysiology (37 cases) consistent with Acute Motor Axonal Neuropathy (**AMAN**)

2016: GBS in times of Zika


Source: WHO website



A Weekly Case Reports of ZIKV Disease and GBS in Six Countries and Bahia, Brazil, 2015–2016



Zika Meningoencephalitis



81-year-old man admitted to ICU 10 days after a 4-week cruise in the area of New Caledonia, Vanuatu, Febrile (39.1° C) and comatose (GCS 6) with left hemiplegia and paresis of the right upper limb.


Transient rash within the next 48 hours.

CSF: WCC 41

◉ (with 98% polymorphonuclear cells), protein 76 mg/dL, CSF/blood glucose ratio 0.75.

CSF positive Zika RT-PCR assay and culture for ZIKV

Acute myelitis due to Zika virus infection




15 yo female, Left hemiparesis, back and arm pain, conjunctival injection, no fever

Neurological Problems Presumed to be Associated with Zika Infection

Peripheral Nervous System Involvement:

- **Guillain-Barre Syndrome**
 - Acute Demyelinating Polyneuropathy
 - Acute Motor Axonal Neuropathy
 - Miller-Fisher variant
- **Neuropathies**



Central Nervous System Involvement:


- Encephalitis
- Myelitis
- Optic neuritis

January 13, 2017


Immune Mediated Pathogenesis vs Direct Viral Neuropathogenicity or Both

6


What is causing Neuro-Zika?




NEAS network in Colombia



Overall structure of the work plan



Overall structure of the work plan



ZikaPlan Bio-Bank: Guiding Principles and Governance

Guiding principles for the ZikaPLAN Biobank:

- 📍 Transparency
- 📍 Fairness: equal access by public and private test developers, small and large companies
- 📍 Respect national laws with regard to the transport or use of patient samples

Virtual bank concept to maximise contributions and minimise transport

A Steering Committee provides oversight with regard to:

- 📍 Virtual bank inventory
- 📍 Request for reference materials/panels
- 📍 Request for evaluations or access to collection/evaluation sites

Diagnostics: Quality Cascade

- 1. Reference Panels (strains)
- 2. Development/Validation Panels (specimens)
- 3. Evaluation Panels

4. Verification Panels

5. Proficiency Panels

3.1. Quality of tests and testing

3.2. Quality of diagnosis

3.3. Data management

Design & Manufacture

Approval for use

Availability in market

Procurement

Storage

Performance

Algorithms used

Result reporting & record

ZikaPLAN evaluation platform

WP 5 Biobanking/Evaluation sites: criteria for selection

- 📍 Senegal, Colombia, Cuba (RELDA), Switzerland


Protocols for evaluation

- 📍 Review CDC and WHO PQ protocols, harmonize and publish
- 📍 All evaluation sites will obtain ethics approval for using the archived specimens and consensus protocol for evaluation

Request for evaluations

- 📍 Call for evaluation: Terms of agreement with companies
- 📍 Requests will be reviewed by the Steering Committee
- 📍 If approved, developers/manufacturers will be referred to the evaluation sites

Overall structure of the work plan



Prospective cohort study involving 17,000 subjects aged 2-59 in 14 different geographic locations in Brazil




14 Clinical Sites in Brazil

- Boa Vista
- Manaus
- Porto Velho
- Cuiabá
- Campo Grande
- Brasília
- São José do Rio Preto
- São Paulo (2): Hospital das Clínicas – FMUSP and Santa Casa de Misericórdia
- Porto Alegre
- Belo Horizonte
- Aracajú
- Recife
- Fortaleza

ZikaPLAN objectives


Addressing knowledge gaps
and needs in key areas of
interest to the current Zika
Outbreak:



Building a sustainable Latin-
American EID Preparedness
and Response capacity



NOVEL INTERVENTIONS FOR PREVENTION OF Aedes-transmitted diseases such as Zika and dengue



Pattamaporn Kittayapong¹, Phanthip Olanratmanee¹, Pongsri Maskhao², Peter Byass³, Valérie Louis⁴, James Logan⁵, Duane Gubler⁶, and Annelies Wilder-Smith^{3,4}

¹Center of Excellence for Vectors and Vector-Borne Diseases, Faculty of Science, Mahidol University at Salaya, Nakhon Pathom, Thailand; ² Faculty of Humanities and Social Sciences, Rajabhat Rajanagarindra University, Chachoengsao, Thailand; ³Center for Global Health Research, Department of Public Health and Clinical Medicine, Umea University, Sweden; ⁴Institute of Public Health, Heidelberg University Medical School, Germany; ⁵Department of Disease Control, London School of Hygiene and Tropical Medicine, ⁶Emerging Infectious Diseases Program, Duke-NUS, Singapore


Hypothesis: Impregnated school uniforms reduce the incidence of dengue infections in school children

Medical Hypotheses (2011)
861–862

A. Wilder-Smith^{a,*}, A. Lover^b, P. Kittayapong^c, G. Burnham^d



Anatapreecha and *et. al.*
Epidemiol. Infection (2005)






RESEARCH ARTICLE

Mitigating Diseases Transmitted by *Aedes* Mosquitoes: A Cluster-Randomised Trial of Permethrin-Impregnated School Uniforms

Pattamaporn Kittayapong^{1,2*}, Phanthip Olanratmanee³, Pongsri Maskhao⁴, Peter Byass⁵, James Logan⁶, Yesim Tozan^{7,8}, Valérie Louis⁷, Duane J. Gubler⁹, Annelies Wilder-Smith^{5,6,10,11*}



SCHOOL UNIFORM PROCESSING

Collecting, coding & packaging school uniforms



7 March 2014 LKC

Courier pick-up & shipping for permethrin-impregnation



Marking and school delivery






RESEARCH ARTICLE

Mitigating Diseases Transmitted by *Aedes* Mosquitoes: A Cluster-Randomised Trial of Permethrin-Impregnated School Uniforms

Pattamaporn Kittayapong^{1,2*}, Phanthip Olanratmanee³, Pongsri Maskhao⁴, Peter Byass⁵, James Logan⁶, Yesim Tozan^{7,8}, Valérie Louis⁷, Duane J. Gubler⁹, Annelies Wilder-Smith^{5,6,10,11*}




No difference in the attack rate

Why?

Rapid washing out of permethrin

Longer lasting insecticides, applications for maternity clothing, for tourists

ZikaPLAN: Wash-resistant clothing



Investigate new wash-resistant technologies that are currently under development

Fibres that contain novel silica shells, that can be weaved into clothing to maintain slow release of repellents over multiple washes

Cone tests, arm-in cage tests, GC and HPLC analysis to determine release rates from the fabric after multiple washes (0-100 washes)



Networks, networks, networks

Birth defect surveillance

NEAS

Evaluation platform-laboratory network

Vector hub

IGOS International GBS Outcome Study

[Home](#) [Organisation](#) [Tools](#) [Extended Newsletter](#) [Contact](#) [IGOS Kids](#) [FAQ](#)

"A world-wide prospective study of INC on prognosis and biomarkers in GBS"



Introducing...

REDe

Research Capacity Network

Research Capacity Network

- Home
- About This Site
- Resources
- Community
- Contact Us

- Groups
- Bookmarks
- Members
- Blogs

What are you looking for?

SEARCH

Welcome to REDE! Tell us what you need in your area

groups » [Research Capacity in Latin America - what is missing?](#) » [Welcome to REDE! Tell us what you need in your area](#)

Bienvenidos a REDE. Esperamos poder trabajar juntos en crear una red integrada de investigadores científicos y ayudara a mejorar las capacidades para investigaciones futuras.

Introduciendose
Hablando donde se encuentra
Comentandonos tres opiniones que consideran generacion un cambio en la comunidad.

Esperamos escuchar de ustedes!
El Equipo Editorial

Research Capacity Network

What are you looking for?

SEARCH

REDe

THE PREPAREDNESS RESEARCH CAPACITY NETWORK FOR THE EU ZIKA CONSORTIA

Research Capacity Network

- Home
- About This Site
- Resources
- Community
- Contact Us

Home


This is the working space for REDe, the research capacity network that is run by the three EU Zika consortia; ZikaPLAN, ZikAlliance and ZikAction. The aim is to build strong partnerships between all research sites running Zika studies in Latin America and the Caribbean so we can work together and develop a sustainable platform for research that can respond to future outbreaks.

REDe Resources

Access resources to guide, teach, support and train you and your team in setting up and running high quality studies.

[LEARN MORE](#)





GHN_EDITORS

Build your professional profile and CV

MEMBERSHIP LEVEL:

★☆☆☆☆

SUBMISSION REQUIRED

REDe aims to build a strong & sustainable network which will be led by core centres of excellent within the region.

These regional centres will coordinate and implement all sorts of capacity development activities such as:

Workshops

Mentoring schemes

Focussed training session

Online courses

e-Learning short courses through the Global Health Network

Conducting Clinical Research:

1. Introduction to Clinical Research – **EACCR**
2. ICH Good Clinical Practice – **MRC The Gambia**
3. The Research Question – **Expert driven content**
4. The Study Protocol: Part one – **Expert driven content**
5. The Study Protocol: Part two – **Expert driven content**
6. Data Safety Monitoring Boards for Clinical Trials – **Expert driven content**
7. Introduction to Informed Consent – **MRC The Gambia**
8. Introduction to Data Management for Clinical Research Studies - **DNDi, UCT**
9. Introduction to Collecting and Reporting Adverse Events – **MRC The Gambia**

Specialist Topics:

1. Introduction to Good Clinical Laboratory Practice – **Gates Foundation GHCC**
2. Ethics of Ancillary Care in Research – **John Hopkins University**
3. Introduction to Reviewing Genomic Research – **Expert driven content**
4. The Retrospective Treatment Outcome Study for Traditional Medicines – **Expert driven content**
5. How to Conduct GCP Inspections/Audits at the Clinical Investigator Site – **Expert driven content**
6. Ethics & Best Practice in Data Sharing in Research – **Expert driven content**
7. Children and Clinical Research – **Nuffield Council on Bioethics**

An initiative funded by the European Union



ZikaPLAN has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 734584.